3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluorocytidine

CAS : 134790-39-9

Ref. 3D-ND08303

Informations sur le produit

• Nom: 3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluorocytidine
• Synonymes: 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidineGemcitabine3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluoro-D-cytidine3',5'-Di-O-benzoyl -2',2'-difluoro-2'-deoxycytidine, 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidine, 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidine (beta isomer), 2'-deoxy-2',2'-difluoro-3',5'-bis-O-(phenylcarbonyl)cytidine, 2,2-Difluoro-2-Deoxycytidine-3,5-Dibenzoate, 3',5'-Di-O-benzoyl-2',2'-difluoro-2'-deoxy cytidine, 3′,5′-Di-O-benzoyl-2′-deoxy-2′,2′-difluorocytidine, Cytidine, 2′-deoxy-2′,2′-difluoro-, 3′,5′-dibenzoate, T9, T9:2’,2’-Difluoro-2’-deoxycytidine-3’,5’-dibenzoate
• CAS: 134790-39-9

Description

Folfirinox is a nucleoside analog that is structurally related to gemcitabine. It is metabolized by the enzyme equilibrative nucleoside transporter (ENT) to form 2'-deoxy-2',2'-difluorocytidine (DFD), which is incorporated into DNA by polymerase chain reaction. Folfirinox has been shown to have antitumor immunity and immunomodulatory effects in mice and humans, and it also has the potential to be used as a radiosensitizer for squamous cell carcinomas. Folfirinox has been found to be effective against pancreatic cancer cells in vitro and in vivo, with a median survival time of 36 days for mice treated with low doses of the drug.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 471.42 g/mol
• Formule: C₂₃H₁₉F₂N₃O₆
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder